Dexrazoxane
- Generic Name
- Dexrazoxane
- Brand Names
- Savene, Totect, Zinecard
- Drug Type
- Small Molecule
- Chemical Formula
- C11H16N4O4
- CAS Number
- 24584-09-6
- Unique Ingredient Identifier
- 048L81261F
- Background
An antimitotic agent with immunosuppressive properties. Dexrazoxane, the (+)-enantiomorph of razoxane, provides cardioprotection against anthracycline toxicity. It appears to inhibit formation of a toxic iron-anthracycline complex. [PubChem]
The Food and Drug Administration has designated dexrazoxane as an orphan drug for use in the prevention or reduction in the incidence and severity of anthracycline-induced cardiomyopathy.
- Indication
For reducing the incidence and severity of cardiomyopathy associated with doxorubicin administration in women with metastatic breast cancer who have received a cumulative doxorubicin hydrochloride dose of 300 mg/m^2 and would benefit from continued doxorubicin therapy. Also approved for the treatment of extravasation from intravenous anthracyclines.
- Associated Conditions
- Doxorubicin Induced Cardiomyopathy, Drug Extravasation
Testing a Standardized Approach to Surgery and Chemotherapy for Type I Pleuropulmonary Blastoma or the Addition of an Anti-cancer Drug, Topotecan, to the Usual Treatment for Types II and III Pleuropulmonary Blastoma
- Conditions
- Pleuropulmonary Blastoma
- Interventions
- Procedure: Biospecimen CollectionProcedure: Computed TomographyProcedure: Bone ScanOther: Patient ObservationProcedure: Ultrasound ImagingProcedure: Echocardiography TestProcedure: Magnetic Resonance ImagingProcedure: Multigated Acquisition ScanProcedure: Positron Emission Tomography
- First Posted Date
- 2024-10-18
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 110
- Registration Number
- NCT06647953
- Locations
- 🇺🇸
Phoenix Childrens Hospital, Phoenix, Arizona, United States
🇺🇸Arkansas Children's Hospital, Little Rock, Arkansas, United States
🇺🇸Valley Children's Hospital, Madera, California, United States
CHIP-AML22/Quizartinib: Quizartinib + Chemotherapy in Newly Diagnosed Pediatric FLT3-ITD+ and NPM1wt AML Patients
- Conditions
- Acute Myeloid Leukemia in Children
- Interventions
- First Posted Date
- 2024-02-16
- Last Posted Date
- 2024-02-16
- Lead Sponsor
- Princess Maxima Center for Pediatric Oncology
- Target Recruit Count
- 60
- Registration Number
- NCT06262438
- Locations
- 🇳🇱
Princess Máxima Center for pediatric oncology, Utrecht, Netherlands
Prevention of Anthracycline-Induced Cardiac Dysfunction With Dexrazoxane in Patients With Diffuse Large-B Cell Lymphoma
- Conditions
- DLBCL - Diffuse Large B Cell Lymphoma
- Interventions
- First Posted Date
- 2024-01-23
- Last Posted Date
- 2024-08-19
- Lead Sponsor
- Stichting Hemato-Oncologie voor Volwassenen Nederland
- Target Recruit Count
- 324
- Registration Number
- NCT06220032
- Locations
- 🇳🇱
NL-Breda-AMPHIA, Breda, Netherlands
🇳🇱NL-Almelo-ZGTALMELO, Almelo, Netherlands
🇳🇱NL-Amstelveen-AMSTELLAND, Amstelveen, Netherlands
Study of DPPG2-TSL-DOX Combined with Hyperthermia in Soft Tissue Sarcoma
- Conditions
- Sarcoma, Soft Tissue
- Interventions
- Drug: DPPG2-TSL-DOX
- First Posted Date
- 2023-05-15
- Last Posted Date
- 2025-02-21
- Lead Sponsor
- Thermosome GmbH
- Target Recruit Count
- 9
- Registration Number
- NCT05858710
- Locations
- 🇩🇪
Helios Klinikum Berlin-Buch GmbH, Berlin, Germany
🇩🇪Klinikum der Universität München (KUM) Campus Großhadern, Munich, Germany
Venetoclax Basket Trial for High Risk Hematologic Malignancies
- Conditions
- Myelodysplastic Syndromes, SecondaryMyelodysplastic Syndromes, Previously TreatedTreatment-Related Acute Myeloid LeukemiaTherapy-Related Myelodysplastic SyndromeAcute Lymphoblastic Leukemia With Failed RemissionMyelodysplastic Syndromes, de NovoLymphoblastic Lymphoma, in RelapseAcute Leukemia of Ambiguous Lineage in RelapseLymphoblastic Lymphoma, RefractoryAcute Leukemia of Ambiguous Lineage
- Interventions
- First Posted Date
- 2022-03-23
- Last Posted Date
- 2025-02-17
- Lead Sponsor
- Andrew E. Place, MD
- Target Recruit Count
- 92
- Registration Number
- NCT05292664
- Locations
- 🇺🇸
Children's Hospital Colorado, Aurora, Colorado, United States
🇺🇸University of California San Francisco-Benioff Children's Hospital, San Francisco, California, United States
🇺🇸Ann & Robert H Lurie Children's Hospital of Chicago, Chicago, Illinois, United States
Use of the Cardioprotectant Dexrazoxane During Congenital Heart Surgery
- First Posted Date
- 2021-08-09
- Last Posted Date
- 2021-08-09
- Lead Sponsor
- University of Texas at Austin
- Target Recruit Count
- 12
- Registration Number
- NCT04997291
- Locations
- 🇺🇸
Dell Children's Medical Center of Central Texas, Austin, Texas, United States
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
- Conditions
- Acute Myeloid Leukemia
- Interventions
- Procedure: Allogeneic Hematopoietic Stem Cell TransplantationProcedure: Biospecimen CollectionProcedure: Bone Marrow AspirationProcedure: Bone Marrow BiopsyProcedure: Computed TomographyOther: Fludeoxyglucose F-18Drug: Liposome-encapsulated Daunorubicin-CytarabineProcedure: Magnetic Resonance ImagingProcedure: Positron Emission TomographyOther: Questionnaire Administration
- First Posted Date
- 2020-03-03
- Last Posted Date
- 2025-05-04
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 1186
- Registration Number
- NCT04293562
- Locations
- 🇨🇦
Kingston Health Sciences Centre, Kingston, Ontario, Canada
🇺🇸Banner Children's at Desert, Mesa, Arizona, United States
🇺🇸Children's Hospital of Alabama, Birmingham, Alabama, United States
Prevention of Heart Failure Induced by Doxorubicin With Early Administration of Dexrazoxane
- First Posted Date
- 2019-04-29
- Last Posted Date
- 2025-03-25
- Lead Sponsor
- University of Arkansas
- Target Recruit Count
- 25
- Registration Number
- NCT03930680
- Locations
- 🇺🇸
University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
Dinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma
- Conditions
- GanglioneuroblastomaHigh Risk Neuroblastoma
- Interventions
- Procedure: Autologous Hematopoietic Stem Cell TransplantationRadiation: External Beam Radiation Therapy
- First Posted Date
- 2018-12-26
- Last Posted Date
- 2025-03-21
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 42
- Registration Number
- NCT03786783
- Locations
- 🇺🇸
Saint Jude Children's Research Hospital, Memphis, Tennessee, United States
🇳🇿Starship Children's Hospital, Grafton, Auckland, New Zealand
🇦🇺The Children's Hospital at Westmead, Westmead, New South Wales, Australia
OlaReDo - Olaratumab and Rechallenge With Doxorubicin in Soft Tissue Sarcoma Patients
- Conditions
- Advanced Soft Tissue Sarcoma
- Interventions
- First Posted Date
- 2018-10-05
- Last Posted Date
- 2020-07-15
- Lead Sponsor
- Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
- Target Recruit Count
- 2
- Registration Number
- NCT03698227
- Locations
- 🇩🇪
Medizinische Fakultät Carl Gustav Carus Medizinische Klinik I Internistische Onkologie, Dresden, Germany
🇩🇪Helios Klinikum Bad Saarow, Bad Saarow, Germany
🇩🇪Helios Klinikum Berlin-Buch Klinik für Onkologie und Palliativmedizin, Berlin, Germany
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.